Your DNA Can Now Predict a Heart Attack Decades Before It Happens: How Polygenic Risk Scores Are Rewriting Cardiovascular Prevention

For decades, predicting who will suffer a heart attack relied on a familiar checklist: cholesterol levels, blood pressure, smoking status, age, and family history. Physicians plugged these numbers into risk calculators and made their best clinical judgment. The system worked reasonably well for people at clear extremes of risk, but it left a vast gray zone in the middle where millions of patients with borderline numbers received ambiguous guidance. Start a statin? Watch and wait? The answer often depended more on the individual physician’s philosophy than on the patient’s actual biology.

Presented By Our Partners

That gray zone is now shrinking. In March 2026, the American College of Cardiology and the American Heart Association released updated dyslipidemia guidelines that, for the first time, formally recognize polygenic risk scores as a risk-enhancing factor in cardiovascular disease assessment. The European Society of Cardiology published a parallel clinical consensus statement in the European Heart Journal. And the National Human Genome Research Institute’s eMERGE Network has begun returning genome-informed risk assessments to 25,000 diverse adults and children across the United States.

Taken together, these three developments mark the moment when genomic risk prediction moved from the research laboratory into the cardiologist’s office. The implications for longevity medicine, preventive cardiology, and how you manage your own health are profound.

What Is a Polygenic Risk Score?

A polygenic risk score, or PRS, is a single number that summarizes the cumulative effect of hundreds or even millions of small genetic variants scattered across your genome. No single variant causes heart disease on its own. Each one nudges your risk up or down by a tiny fraction. But when you add them all together, the combined signal can be powerful.

Think of it this way: if your genome were a symphony orchestra, each genetic variant would be a single musician playing a note that is barely audible on its own. A polygenic risk score captures the combined volume of the entire ensemble. Some people carry an orchestra that plays loudly in the direction of coronary artery disease. Others carry one that plays quietly.

The mathematics behind a PRS draws on genome-wide association studies, or GWAS, which scan hundreds of thousands of people to identify which genetic variants appear more often in those who develop a specific disease. Researchers then weight each variant by its effect size and sum them into a composite score. The result is a probability estimate that can be calculated from a single saliva sample or blood draw, often for under a hundred dollars.

The 2026 ACC/AHA Milestone

The updated 2026 ACC/AHA guidelines on dyslipidemia management represent a watershed moment for genomic medicine. For the first time, polygenic risk scores are listed alongside coronary artery calcium scoring, ankle-brachial index, and high-sensitivity C-reactive protein as recognized risk-enhancing factors that physicians can use to guide statin therapy decisions.

The practical application centers on the patient who falls into the borderline or intermediate risk category on the standard Pooled Cohort Equations, the calculator that estimates ten-year atherosclerotic cardiovascular disease risk. When a patient’s number hovers near the threshold where a statin might be recommended, a high polygenic risk score can tip the decision toward treatment. A low score can provide reassurance that watchful waiting is reasonable.

The guidelines specifically cite a multi-ancestry coronary artery disease PRS developed and validated by Allelica, a genomics company, using data from 29,389 individuals across African, European, Hispanic, and South Asian genetic backgrounds. That score demonstrated an average odds ratio of 1.57 per standard deviation, meaning that for each standard deviation increase in the score, the risk of coronary artery disease rose by 57 percent. Across validation datasets that included more than 190,000 participants of diverse ancestry, the score outperformed all previously published CAD polygenic risk scores.

What makes this recognition significant is not simply that the science has improved. It is that the gatekeepers of clinical practice, the ACC and AHA guideline committees, have decided the evidence is strong enough to change how physicians make decisions at the point of care.

What the European Society of Cardiology Is Saying

On the other side of the Atlantic, the European Society of Cardiology’s Council on Cardiovascular Genomics, the ESC Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology jointly published a clinical consensus statement in the European Heart Journal in early 2025. That statement laid the intellectual groundwork for much of what the ACC/AHA guidelines now codify.

The ESC consensus acknowledges that while European guidelines do not yet advocate routine PRS use in clinical practice, polygenic risk scores are commercially available and increasingly sought by clinicians, health systems, and patients. The statement positions PRS as most meaningful when applied as an adjunct to existing risk calculators in patients near clinical decision thresholds, which is precisely the borderline-risk population where traditional tools struggle most.

One of the most clinically relevant findings highlighted in the consensus is that PRS adds the greatest value in women and younger individuals, two groups that conventional risk calculators tend to underestimate. Standard risk equations weight age heavily, which means a 35-year-old woman with genuinely high genetic risk may appear low-risk on paper simply because she has not yet accumulated enough birthdays to trigger concern. A PRS can reveal that her lifetime trajectory is far more dangerous than her current numbers suggest.

The ESC statement also calls for standardized methods, validation across ancestries, and prospective outcome trials before broader adoption. This is the measured language of an institution that recognizes the technology is ready for targeted clinical use but not yet for universal screening.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The eMERGE Network: 25,000 Genomes in the Clinic

Perhaps the most ambitious real-world test of polygenic risk scoring is the eMERGE IV study, funded by the National Human Genome Research Institute. This program has developed a framework for returning PRS-based genome-informed risk assessments to 25,000 diverse adults and children at clinical sites across the United States.

From an initial list of 23 candidate conditions, the eMERGE researchers selected ten for clinical implementation based on PRS performance, medical actionability, and potential clinical utility. Those ten include atrial fibrillation, breast cancer, chronic kidney disease, coronary heart disease, hypercholesterolemia, prostate cancer, asthma, type 1 diabetes, obesity, and type 2 diabetes.

What sets eMERGE apart is its commitment to diverse populations. One of the persistent criticisms of polygenic risk scores has been that most were developed and validated in cohorts of European descent, raising concerns about accuracy and equity in African American, Hispanic, Asian, and other populations. The eMERGE pipeline uses genetic ancestry to calibrate PRS mean and variance, training and testing model parameters on genetically diverse data from 13,475 participants of the All of Us Research Program.

Early results from the provider side are encouraging. Healthcare professionals reported being "extremely or very confident" in disclosing high-risk PRS results to patients in 78 percent of cases. And when PRS findings were shared, they impacted clinical decision-making in 67 percent of encounters. In four specific cases, the PRS result led to new statin recommendations. In 23 additional cases, physicians modified management plans to include lifestyle adjustments and increased monitoring.

These numbers may sound modest, but consider the scale. If 25,000 patients receive PRS results and 67 percent of those results change a clinical conversation, that is more than 16,000 modified care decisions from a single study. Multiply that by the millions of patients who could eventually be tested, and the downstream impact on heart attack prevention, cancer screening, and chronic disease management becomes enormous.

The Reclassification Effect: Who Gets Moved?

The most tangible clinical impact of PRS lies in reclassification, the process by which a patient’s risk category shifts after incorporating genetic information. Large-scale analyses have shown that adding PRS to the standard Pooled Cohort Equations reclassifies approximately 20 percent of borderline-risk younger adults into the statin-eligible intermediate-risk category. At the same time, it down-classifies another 20 percent into the low-risk category, sparing them from unnecessary medication.

For individuals younger than 50 with borderline ASCVD risk scores, the numbers are striking. In one analysis, 591 of 4,373 patients (roughly 14 percent) moved from borderline into intermediate risk, meeting the threshold for statin initiation. Meanwhile, 3,198 of 7,477 patients (about 43 percent) with borderline or intermediate risk moved down to low risk, where statin therapy would not be recommended.

This bidirectional reclassification is important. The conversation about PRS often focuses on identifying high-risk individuals who are currently being missed. But the ability to identify low-risk individuals who are currently being overtreated is equally valuable. Statins are generally safe drugs, but they are not free of side effects, costs, or the psychological burden of being told you need medication for a chronic condition. Accurately identifying people who do not need treatment is a genuine clinical benefit.

Statins Work Harder When Genetic Risk Is High

One of the more compelling recent findings is that statin effectiveness varies by polygenic risk status. Research published in 2025 and 2026 demonstrates that the magnitude of statin benefit becomes progressively stronger across low, intermediate, and high PRS groups. Patients in the highest polygenic risk tier experience the largest absolute risk reduction from statin therapy, while those in the lowest tier receive the smallest benefit.

This finding aligns with biological logic. Statins lower LDL cholesterol, and individuals with high genetic predisposition to coronary artery disease are precisely the people for whom LDL reduction matters most. Their arteries are primed for plaque accumulation by hundreds of small genetic nudges, and removing one of the key substrates for that accumulation, circulating LDL, produces an outsized protective effect.

Data from the UK Biobank confirms this pattern. Individuals in the highest PRS percentiles carry a three-to-fivefold higher risk of coronary artery disease compared to average. When these individuals take statins, their relative and absolute risk reductions are substantially larger than what is observed in the general population.

The clinical implication is that PRS can help physicians not only decide whether to prescribe a statin but also set appropriate expectations for how much benefit the patient is likely to receive.

Hidden Plaque in Seemingly Healthy People

A particularly striking finding from the PROACT clinical trials and related research is that among individuals with low clinical risk scores but high polygenic risk, roughly half had subclinical coronary plaque visible on imaging. These are people who would pass every standard risk screening with flying colors: normal cholesterol, normal blood pressure, no diabetes, no smoking history. Their ten-year risk calculators would say they are safe. But their arteries tell a different story.

This disconnect between clinical risk scores and actual arterial disease is one of the strongest arguments for incorporating PRS into routine care. Traditional risk factors are snapshots of where you are right now. Polygenic risk reflects where your biology has been pushing you since conception. A 40-year-old with a high PRS may have normal labs today, but those hundreds of pro-atherogenic genetic variants have been quietly nudging lipid metabolism, vascular inflammation, and endothelial function in an unfavorable direction for four decades.

Finding these patients before their first cardiac event, rather than after, is the foundational promise of precision cardiovascular medicine.

The Equity Challenge

No discussion of polygenic risk scores is complete without addressing the equity gap. Most large-scale GWAS that underpin PRS development have been conducted in populations of European descent. This means that PRS accuracy, measured by the proportion of disease variance explained, is substantially lower in African, Hispanic, East Asian, and South Asian populations.

The Allelica multi-ancestry score cited in the 2026 ACC/AHA guidelines represents a deliberate effort to close this gap. By developing and validating ancestry-specific scores using cohorts that include African, European, Hispanic, and South Asian participants, the researchers demonstrated that multi-ancestry approaches can achieve clinically meaningful performance across populations.

The eMERGE Network has taken a similar approach, calibrating its PRS pipeline against the genetically diverse All of Us cohort. But researchers and clinicians acknowledge that much more work is needed. The ESC consensus statement specifically calls for broader validation across ancestries as a prerequisite for widespread adoption.

If polygenic risk scores are to fulfill their promise of predicting and preventing disease, they must work equitably for everyone. A tool that benefits only populations of European descent would deepen existing health disparities rather than reduce them.

What This Means for You

The formal recognition of polygenic risk scores in the 2026 ACC/AHA guidelines changes the practical landscape for anyone interested in proactive cardiovascular health.

If you are between 30 and 50, with borderline cholesterol or a family history of early heart disease, a polygenic risk score can provide information that no blood test or imaging study currently captures. It can tell you whether the genetic orchestra playing inside your cells is loud or quiet when it comes to coronary artery disease.

If you are a woman who has been told your cardiovascular risk is low because you are young, a PRS may reveal that your lifetime trajectory deserves closer attention than your current numbers suggest.

If you are already taking a statin and wondering whether the benefit justifies the commitment, a PRS can help your physician estimate how much risk reduction you are actually receiving.

Here is what you can do now. First, ask your primary care physician or cardiologist whether polygenic risk scoring is available through their practice or a connected genomics service. Several clinical-grade PRS tests are commercially available today. Second, if you already have raw genotype data from a direct-to-consumer service, some clinical genomics companies can calculate a validated PRS from existing data, though clinical-grade tests are preferred. Third, understand that a PRS is one input among many. It does not replace cholesterol testing, blood pressure monitoring, or lifestyle optimization. It adds a layer of genetic context that makes those other inputs more meaningful.

The era of treating cardiovascular risk as a simple arithmetic problem using age, cholesterol, and blood pressure is ending. In its place, a more nuanced, more personal, and more accurate model of prediction is emerging. Your DNA has been shaping your cardiovascular destiny since the moment you were conceived. For the first time in clinical history, physicians can read that signal and act on it before the damage is done.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.